Work

Sirolimus Associated Pneumonitis after Nonmyeloablative Peripheral Blood Stem Cell Transplant for Sickle Cell Disease

Year: 2008

Type: article

Abstract: Sirolimus is an immunosuppressant commonly used in solid organ transplantation as an alternative to corticosteroids or calcineurin inhibitors. Common side effects include hyperlipidemia, arthralgias, and noncardiac peripheral edema. Pulmonary toxicity is increasingly recognized after solid organ transplants [1-3]. Here we report the first case of sirolimus-associated pneumonitis (SAP) in a peripheral blood stem cell transplant (PBSCT) patient.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2007.11.001

Authors: Matthew M. Hsieh, M. Beth Link, John F. Tisdale

Institutions: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650